Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The
Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.
January 26, 2001
Marc RubinChairman of the Board
Peter TraberPresident, Chief Executive Officer, Chief Medical Officer, Director
Jack CallicuttChief Financial Officer
Harold ShlevinChief Operating Officer, Secretary
Eliezer ZomerExecutive Vice President - Manufacturing and Product Development
J. Rex HortonExecutive Director - Regulatory Affairs and Quality Assurance
Gilbert AmelioIndependent Director
Kevin FreemanIndependent Director
Arthur GreenbergIndependent Director
John MauldinIndependent Director
Gilbert OmennIndependent Director
4960 Peachtree Industrial Blvd Ste 240 Berkeley Lake, GA United States Phone: +1 678 620-3186 Fax: +1 770 864-1327 www.galectintherapeutics.com
Net income grew by 36.86%, year over year, to a loss of (U.S.)$0.15 per share during the most recently completed quarter.